{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:34:46Z","timestamp":1782963286824,"version":"3.54.5"},"reference-count":71,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DBT Ramalingaswami Re-entry Fellowship project","award":["BT\/RLF\/Re-entry\/44\/2018"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/44\/2018"]}]},{"name":"DBT Ramalingaswami Re-entry Fellowship project","award":["CRG\/2020\/001213"],"award-info":[{"award-number":["CRG\/2020\/001213"]}]},{"name":"DBT Ramalingaswami Re-entry Fellowship project","award":["54\/14\/03\/2022-BRNS\/10207"],"award-info":[{"award-number":["54\/14\/03\/2022-BRNS\/10207"]}]},{"name":"DBT Ramalingaswami Re-entry Fellowship project","award":["2020\u20132021"],"award-info":[{"award-number":["2020\u20132021"]}]},{"name":"DBT Ramalingaswami Re-entry Fellowship project","award":["2021\u20132023"],"award-info":[{"award-number":["2021\u20132023"]}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry\/44\/2018"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/44\/2018"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2020\/001213"],"award-info":[{"award-number":["CRG\/2020\/001213"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["54\/14\/03\/2022-BRNS\/10207"],"award-info":[{"award-number":["54\/14\/03\/2022-BRNS\/10207"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["2020\u20132021"],"award-info":[{"award-number":["2020\u20132021"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["2021\u20132023"],"award-info":[{"award-number":["2021\u20132023"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry\/44\/2018"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/44\/2018"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["CRG\/2020\/001213"],"award-info":[{"award-number":["CRG\/2020\/001213"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["54\/14\/03\/2022-BRNS\/10207"],"award-info":[{"award-number":["54\/14\/03\/2022-BRNS\/10207"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["2020\u20132021"],"award-info":[{"award-number":["2020\u20132021"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["2021\u20132023"],"award-info":[{"award-number":["2021\u20132023"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VIT SEED Grant","award":["BT\/RLF\/Re-entry\/44\/2018"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/44\/2018"]}]},{"name":"VIT SEED Grant","award":["CRG\/2020\/001213"],"award-info":[{"award-number":["CRG\/2020\/001213"]}]},{"name":"VIT SEED Grant","award":["54\/14\/03\/2022-BRNS\/10207"],"award-info":[{"award-number":["54\/14\/03\/2022-BRNS\/10207"]}]},{"name":"VIT SEED Grant","award":["2020\u20132021"],"award-info":[{"award-number":["2020\u20132021"]}]},{"name":"VIT SEED Grant","award":["2021\u20132023"],"award-info":[{"award-number":["2021\u20132023"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Targeted protein degradation is a new aspect in the field of drug discovery. Traditionally, developing an antibiotic includes tedious and expensive processes, such as drug screening, lead optimization, and formulation. Proteolysis-targeting chimeras (PROTACs) are new-generation drugs that use the proteolytic mechanism to selectively degrade and eliminate proteins involved in human diseases. The application of PROTACs is explored immensely in the field of cancer, and various PROTACs are in clinical trials. Thus, researchers have a profound interest in pursuing PROTAC technology as a new weapon to fight pathogenic viruses and bacteria. This review highlights the importance of antimicrobial PROTACs and other similar \u201cPROTAC-like\u201d techniques to degrade pathogenic target proteins (i.e., viral\/bacterial proteins). These techniques can perform specific protein degradation of the pathogenic protein to avoid resistance caused by mutations or abnormal expression of the pathogenic protein. PROTAC-based antimicrobial therapeutics have the advantage of high specificity and the ability to degrade \u201cundruggable\u201d proteins, such as nonenzymatic and structural proteins.<\/jats:p>","DOI":"10.3390\/antibiotics11121717","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T01:42:02Z","timestamp":1669686122000},"page":"1717","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-3048","authenticated-orcid":false,"given":"Janarthanan","family":"Venkatesan","sequence":"first","affiliation":[{"name":"Drug Discovery Unit (DDU), Centre for Biomaterials, Cellular, and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India"},{"name":"School of Advanced Sciences (SAS), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-8518","authenticated-orcid":false,"given":"Dhanashree","family":"Murugan","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit (DDU), Centre for Biomaterials, Cellular, and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India"},{"name":"School of Biosciences and Technology (SBST), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-0330","authenticated-orcid":false,"given":"Loganathan","family":"Rangasamy","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit (DDU), Centre for Biomaterials, Cellular, and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"692574","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC Technology: Opportunities and Challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4236\/abc.2013.32029","article-title":"Administration of Grape Seed Extract Alleviates Age-Associated Decline in Ubiquitin-Proteasome System and Cardiomyocyte Apoptosis in Rats","volume":"3","author":"Vijayakumar","year":"2013","journal-title":"Adv. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ddtec.2018.11.001","article-title":"Ligand-Induced Genetic Degradation as a Tool for Target Validation","volume":"31","author":"Yesbolatova","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Choi, S.R., Wang, H.M., Shin, M.H., and Lim, H.-S. (2021). Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126407"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_8","first-page":"1","article-title":"PROTACs: Great Opportunities for Academia and Industry","volume":"4","author":"Sun","year":"2019","journal-title":"Sig. Transduct. Target"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ddtec.2018.12.003","article-title":"Identification and Characterization of Cancer Vulnerabilities via Targeted Protein Degradation","volume":"31","author":"Winter","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_10","unstructured":"(2022, November 11). Protacdb Server. Available online: http:\/\/cadd.zju.edu.cn\/protacdb\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_12","unstructured":"(2022, November 02). Protein Degradation with PROTAC Protein Degraders. Available online: https:\/\/www.arvinas.com\/."},{"key":"ref_13","unstructured":"(2022, November 02). Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC\u00ae Protein Degrader ARV-471 | Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/arvinas-and-pfizer-announce-global-collaboration-develop."},{"key":"ref_14","unstructured":"(2022, November 02). Accutar Biotech. Available online: https:\/\/www.accutarbio.com\/workflow\/."},{"key":"ref_15","unstructured":"(2022, November 02). Understanding Protein Degradation\u2013Bristol Myers Squibb. Available online: https:\/\/www.bms.com\/media\/media-library\/scientific-media-resources\/understanding-protein-degradation-and-resources.html."},{"key":"ref_16","unstructured":"(2022, November 02). Dialectic. Available online: https:\/\/www.dtsciences.com\/."},{"key":"ref_17","unstructured":"(2022, November 02). Foghorntx Therapeutics Pipeline. Available online: https:\/\/foghorntx.com\/pipeline\/."},{"key":"ref_18","unstructured":"(2022, November 02). Therapeutic Pipeline. Available online: https:\/\/www.kymeratx.com\/pipeline\/."},{"key":"ref_19","unstructured":"(2022, November 02). Nurix Pipeline. Available online: https:\/\/www.nurixtx.com\/pipeline\/."},{"key":"ref_20","unstructured":"(2022, November 02). Targeted Protein Degradation\u2013C4 Therapeutics. Available online: https:\/\/c4therapeutics.com\/our-science\/targeted-protein-degradation."},{"key":"ref_21","unstructured":"(2022, November 03). Cullgen. Available online: https:\/\/www.cullgen.com."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted Protein Degraders Crowd into the Clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.3389\/fimmu.2018.02697","article-title":"Specific MHC-I Peptides Are Induced Using PROTACs","volume":"9","author":"Jensen","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended Pharmacodynamic Responses Observed upon PROTAC-Mediated Degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/acschembio.1c00681","article-title":"Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6","volume":"16","author":"Cao","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wu, Y., Yang, Y., Wang, W., Sun, D., Zheng, M., Zhou, Y., Liang, J., Zhu, M., Li, H., and Chen, L. (2022). PROTAC Technology as a Novel Tool to Identify the Target of Lathyrane Diterpenoids. Biol. Med. Chem.","DOI":"10.26434\/chemrxiv-2022-5t93k"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-Targeting Chimera (PROTAC) for Targeted Protein Degradation and Cancer Therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as Emerging Anticancer Therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/acsmedchemlett.9b00042","article-title":"PROTAC Molecules for the Treatment of Autoimmune Disorders","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.arr.2022.101616","article-title":"Targeted Protein Degraders March towards the Clinic for Neurodegenerative Diseases","volume":"78","author":"Kumar","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1021\/acsinfecdis.1c00203","article-title":"Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?","volume":"7","author":"Powell","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4155\/fmc-2022-0005","article-title":"Proteolysis Targeting Chimeras in Antiviral Research","volume":"14","author":"Desantis","year":"2022","journal-title":"Future Med. Chem."},{"key":"ref_33","unstructured":"(2022, November 08). Trial of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03888612."},{"key":"ref_34","unstructured":"(2022, November 08). A Phase 1\/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE\u00ae) in Patients with ER+\/HER2- Locally Advanced or Metastatic Breast Cancer-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04072952."},{"key":"ref_35","unstructured":"Accutar Biotechnology Inc. (2022, November 02). A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients with Estrogen Receptor Positive\/Human Epidermal Growth Factor Receptor 2 Negative (ER+\/HER2-) Locally Advanced or Metastatic Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_36","unstructured":"(2022, November 08). A Study of ARV-766 Given by Mouth in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Prior Approved Systemic Therapies-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05067140."},{"key":"ref_37","unstructured":"(2022, November 08). Study to Evaluate the Safety and Tolerability of CC-94676 in Participants with Metastatic Castration-Resistant Prostate Cancer-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04428788."},{"key":"ref_38","unstructured":"(2022, November 08). A Study of DT2216 in Relapsed\/Refractory Malignancies-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04886622."},{"key":"ref_39","unstructured":"(2022, November 09). FHD-609 in Subjects with Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04965753."},{"key":"ref_40","unstructured":"(2022, November 09). A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients with Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04772885."},{"key":"ref_41","unstructured":"Kymera Therapeutics, Inc. (2022, November 02). A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK\/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-Cell NHL, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_42","unstructured":"Nurix Therapeutics, Inc. (2022, November 02). A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton\u2019s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed\/Refractory B-Cell Malignancies, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_43","unstructured":"(2022, November 09). A Study of NX-5948 in Adults with Relapsed\/Refractory B-Cell Malignancies-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05131022."},{"key":"ref_44","unstructured":"(2022, November 09). A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors-Tabular View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05355753."},{"key":"ref_45","first-page":"277","article-title":"The Antibiotic Resistance Crisis","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pbiomolbio.2019.11.005","article-title":"Targeted Protein Degradation in Antibacterial Drug Discovery?","volume":"152","author":"Gopal","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC That Antagonizes and Destroys the Cancer-Forming X-Protein of the Hepatitis B Virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","unstructured":"Tan, S.-L. (2006). HCV NS3-4A Serine Protease. Hepatitis C Viruses: Genomes and Molecular Biology, Horizon Bioscience."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small Molecule Degraders of the Hepatitis C Virus Protease Reduce Susceptibility to Resistance Mutations","volume":"10","author":"Du","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-022-29690-x","article-title":"An Anti-Influenza A Virus Microbial Metabolite Acts by Degrading Viral Endonuclease PA","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","article-title":"Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100030","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of Oseltamivir-Based Novel PROTACs as Degraders Targeting Neuraminidase to Combat H1N1 Influenza Virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","article-title":"Targeting the SARS-COV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RiboTAC) Degraders","volume":"6","author":"Haniff","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21662","DOI":"10.1002\/anie.202105942","article-title":"Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**","volume":"60","author":"Su","year":"2021","journal-title":"Angew. Chem. -Int. Ed."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hahn, F., Hamilton, S.T., Wangen, C., Wild, M., Kicuntod, J., Br\u00fcckner, N., Follett, J.E.L., Herrmann, L., Kheimar, A., and Kaufer, B.B. (2021). Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. IJMS, 22.","DOI":"10.3390\/ijms222312858"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"113814","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-Based PROTACs as Pan-Coronavirus Antiviral Agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Zheng, R., Liu, S., Disoma, C., Du, A., Li, S., Chen, Z., Dong, Z., Zhang, Y., and Li, S. (2022). Host E3 Ligase HUWE1 Attenuates the Proapoptotic Activity of the MERS-CoV Accessory Protein ORF3 by Promoting Its Ubiquitin-Dependent Degradation. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.101584"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Moreno-Cinos, C., Goossens, K., Salado, I.G., Van Der Veken, P., De Winter, H., and Augustyns, K. (2019). ClpP Protease, a Promising Antimicrobial Target. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092232"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature20122","article-title":"Arginine Phosphorylation Marks Proteins for Degradation by a Clp Protease","volume":"539","author":"Trentini","year":"2016","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41589-019-0265-y","article-title":"Structure of McsB, a Protein Kinase for Regulated Arginine Phosphorylation","volume":"15","author":"Suskiewicz","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs Mediate Targeted Protein Degradation in Bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1074\/jbc.RA118.002251","article-title":"The Antibiotic Cyclomarin Blocks Arginine-Phosphate-Induced Millisecond Dynamics in the N-Terminal Domain of ClpC1 from Mycobacterium Tuberc","volume":"293","author":"Brennich","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1002\/anie.201101740","article-title":"The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease","volume":"50","author":"Schmitt","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Junk, L., Schmiedel, V., Guha, S., Greb, P., Fischel, K., Rumpel, K., Kaur, P., Krishnamurthy, R., Narayanan, S., and Kofink, C. (2022). BacPROTAC-Induced Degradation of ClpC1 as a New Strategy against Drug-Resistant Mycobacteria. Chemrxiv.","DOI":"10.26434\/chemrxiv-2022-8hnrh"},{"key":"ref_65","first-page":"674416","article-title":"Pyrazinamide Triggers Degradation of Its Target Aspartate Decarboxylase","volume":"11","author":"Gopal","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.chembiol.2012.04.008","article-title":"Inhibitor Mediated Protein Degradation","volume":"19","author":"Long","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_67","unstructured":"Su, X., Lu, F., Qi, F., Wen, T., Bai, M., and Wang, J. (2022, November 24). Compound for Degrading Deoxyribonucleic Acid (DNA) Polymerase, and Use Thereof. Available online: https:\/\/patentscope2.wipo.int\/search\/en\/detail.jsf?docId=WO2022156764&_gid=202230."},{"key":"ref_68","unstructured":"Zhou, H., Wu, S., and Xu, Z. (2022, November 17). A kind of Oseltamivir PROTAC Compound and its Preparation Method and Application in Anti-Influenza Virus Drug. CN112592331B, 22 October 2021. Available online: https:\/\/patents.google.com\/patent\/CN112592331B\/en."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered Bioorthogonal POLY-PROTAC Nanoparticles for Tumour-Specific Protein Degradation and Precise Cancer Therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.str.2019.06.005","article-title":"Structural Basis for Recruitment of DAPK1 to the KLHL20 E3 Ligase","volume":"27","author":"Chen","year":"2019","journal-title":"Structure"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e45457","DOI":"10.7554\/eLife.45457","article-title":"Targeted Degradation of Aberrant Tau in Frontotemporal Dementia Patient-Derived Neuronal Cell Models","volume":"8","author":"Silva","year":"2019","journal-title":"eLife"}],"updated-by":[{"DOI":"10.3390\/antibiotics14121237","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000}}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/12\/1717\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:38:01Z","timestamp":1765190281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/12\/1717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["antibiotics11121717"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11121717","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}